Literature DB >> 15968200

Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3.

Judit Pallares1, Jose Luis Martínez-Guitarte, Xavier Dolcet, David Llobet, Montserrat Rue, José Palacios, Jaime Prat, Xavier Matias-Guiu.   

Abstract

Evasion of apoptotic cell death plays a key role in cancer development. Survivin is a member of the inhibitor of apoptosis proteins, which also has a role in the control of cell division. Survivin may be overexpressed in some tumors and has been suggested to be related to PTEN, beta-catenin, p53 [all of them frequently abnormal in endometrial carcinomas (ECs)], and STAT-3. A tissue microarray was constructed from paraffin-embedded blocks of 95 ECs, previously studied for microsatellite instability and for alterations in PTEN, k-RAS, and CTNNB-1. Immunohistochemical evaluation included 1) survivin, 2) markers of cell proliferation and apoptosis (Ki67-MIB1 and M 30-neoepitope cytokeratin 18), and 3) proteins involved in cell signaling pathways (PTEN, phospho-AKT, beta-catenin, p53, and STAT-3). Survivin expression was frequent in ECs (75.95%) but did not show any statistical significant correlation with histological type and grade, stage, overall survival, or mitotic and apoptotic indexes. Survivin expression had a statistical significant correlation with decreased PTEN expression (r = -0.383, p = 0.001), increased phospho-AKT (r = 0.70, p < 0.001), and positive STAT-3 immunostaining (r = 0.6, p < 0.001). Survivin expression did not show statistical correlation with either beta-catenin or p53 alterations. The results suggest that increased survivin expression is frequent in ECs and may be dependent on STAT-3 and PI3 K/AKT activation. Because PTEN abnormalities are very frequent in ECs, the results from this study indicate that PTEN may interfere with the process of apoptosis and cell proliferation by promoting survivin expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968200     DOI: 10.1097/01.pgp.0000163849.37129.d4

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  15 in total

Review 1.  Role of the Survivin gene in pathophysiology.

Authors:  Fengzhi Li; Michael G Brattain
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation.

Authors:  Judit Pallares; David Llobet; Maria Santacana; Nuria Eritja; Ana Velasco; Dolors Cuevas; Susana Lopez; Victor Palomar-Asenjo; Andree Yeramian; Xavier Dolcet; Xavier Matias-Guiu
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

3.  Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells.

Authors:  Melanie M Scully; Leslie K Palacios-Helgeson; Lah S Wah; Twila A Jackson
Journal:  Horm Cancer       Date:  2014-05-21       Impact factor: 3.869

Review 4.  Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications.

Authors:  Laura Cerezo; Higinia Cárdenes; Helen Michael
Journal:  Clin Transl Oncol       Date:  2006-04       Impact factor: 3.405

5.  KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels.

Authors:  David Llobet; Nuria Eritja; Monica Domingo; Laura Bergada; Cristina Mirantes; Maria Santacana; Judit Pallares; Anna Macià; Andree Yeramian; Mario Encinas; Gema Moreno-Bueno; Jose Palacios; Robert E Lewis; Xavier Matias-Guiu; Xavi Dolcet
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

6.  Targeting the Akt/mTOR pathway in Brca1-deficient cancers.

Authors:  T Xiang; Y Jia; D Sherris; S Li; H Wang; D Lu; Q Yang
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

7.  Sex hormone regulation of survivin gene expression.

Authors:  Nancy H Nabilsi; Russell R Broaddus; Adrienne S McCampbell; Karen H Lu; Henry T Lynch; Lee-May Chen; David S Loose
Journal:  J Endocrinol       Date:  2010-08-26       Impact factor: 4.286

8.  DcR1 expression in endometrial carcinomas.

Authors:  Jordi Tarragona; Nuria Llecha; Maria Santacana; Susana Lopez; Sonia Gatius; David Llobet; Xavier Dolcet; Victor Palomar-Asenjo; Francisco Javier Gonzalez-Tallada; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2009-11-20       Impact factor: 4.064

9.  Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.

Authors:  Maria Lambropoulou; Nikolaos Papadopoulos; Grigoris Tripsianis; George Alexiadis; Olga Pagonopoulou; Anastasia Kiziridou; Vassilios Liberis; Stylianos Kakolyris; Ekaterini Chatzaki
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

10.  pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant.

Authors:  A Brunner; P Riss; G Heinze; H Brustmann
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.